...BARCELONA Spain Jan. 26 2011 /- PharmaNet Development ...In conjunction with the termination of this relationship Dr. Maria Cr...The companies will independently continue to invest in and provide to... About PharmaNet Development Group Inc. ...

BARCELONA, Spain, Jan. 26, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc. and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

In conjunction with the termination of this relationship, Dr. Maria Cruz Caturla, Anapharm Europe's majority shareholder, has purchased PharmaNet's minority ownership interest, thus becoming the sole owner of the company.

The companies will independently continue to invest in, and provide to clients, bioanalytical services in their respective laboratory facilities. Additionally, to the extent necessary, the companies will provide coordinated support for those client projects undertaken jointly during the term of the joint venture.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.

About Anapharm Europe, S.L.

Anapharm Europe is a leading provider of bioanalytical services for the pharmaceutical, biopharmaceutical and generic firms, working with the most prestigious clinical pharmacology units in Spain, the rest of Europe, and around the world. Located in Barcelona, Spain, its GLP-certified laboratory has high-capacity, state-of-the-art equipment and'/>"/>

(Date:7/30/2015)... , July 30, 2015 Eisai Inc. ... the United States , European Union ... EMA and MHLW, respectively) for eribulin, for the treatment ... have received prior chemotherapy for advanced or metastatic disease. ... data from a pivotal global Phase 3 clinical trial ...

... Oncobiologics announced today that it has signed two ... early-stage biotech company, and involves worldwide licensing for an ... based large pharmaceutical company to conduct research focused on ... The identity of the client firm was not disclosed ...

(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...

(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...

(Date:7/31/2015)... ... 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening ... first provider of Exilis non-surgical fat reduction in New York. Due to its ... large International clientele. Many patients travel to New York to get their non-surgical ...

(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...

... Than 33 Percent Traffic GrowthJERSEY CITY, N.J., March ... interactive marketing company that specializes in connecting health ... announced strong growth during 2008, along with significant ... site QualityHealth.com. The Company has used the down ...

... Exhibit , www.donaldverger.com PORTLAND, Maine, March 3 A ... a period of three days at the start of the ... compelled to turn his experience into something positive. , ... Verger for using his considerable talents to help the Innocence ...

... caused by faulty signalling in the brain, according to ... Psychiatry . In the biggest study of its kind, ... people with the condition have identified 49 genes that ... to controls. , Many of these genes are involved ...

... premier surgical and medical equipment supplier, now sells its DRE Integra AV-S ... be utilized as patients attempt to breathe spontaneously. , ... (Vocus) March ... of the Year by Business First of Louisville, continues expanding its ...

... scientists receive prestigious research fellowships worth US$1.5 million each , ... ... scientists have been awarded research grants from the National Research Foundation ... Singapore. These scientists hail from six nations including China, Estonia, ...